Antigenic variation in a major discontinuous site (site D) of foot-and-mouth disease virus (FMDV) of serotype C has been evaluated with neutralizing monoclonal antibodies. Isolates representing the major evolutionary sublines previously defined for serotype C were compared. Extensive variation, comparable to that of continuous epitopes within the hypervariable immunodominant site A (the VP1 G-H loop), was found. The amino acid sequences of the complete capsids of three antigenically highly divergent FMDVs (C, Haute Loire-Fr/69, C. Argentina/69, and C3 Argentina/85) have been determined and compared with the corresponding sequences previously determined for seven additional type C viruses. Differences in antigenicity are due to a very limited number of substitutions of surface amino acids accessible to antibodies and located within antigenic sites previously identified on FMDV. A significant number of residues at these positions were also replaced in monoclonal antibody escape mutants. Depending on the variants compared, replacements within site A or at site D, or at both sites, contributed significantly to their antigenic differences. Examples of divergence mediated by a few amino acid replacements were found among FMDVs of Europe and South America. The results suggest that within a serotype of FMDV, antigenically highly divergent viruses can arise in the field by very limited sequence variation at exposed key residues of each of several antigenic sites.
Picornaviridace family, is the etiological agent of an economically important disease of cattle and other cloven-hoofed animals (for reviews, see references 24 and 47). Inactivatedvirus vaccines are in use in many countries. However, a vaccine origin for some outbreaks in Europe has been proposed (8) , and a nonvaccination policy has been compulsory in the European Community since 1992. These and various other reasons make a synthetic FMD vaccine an attractive possibility (13) . Experimental peptide or recombinant vaccines (10, 15, 20) have been based mainly on a major continuous antigenic site of FMDV (site A) (10, 49, 56) located within a mobile surface loop (the G-H loop) of capsid protein VPI (2, 32, 43) . However, site A is genetically and antigenically hypervariable, even within each of the seven serotypes identified (36, 38 ; for a review, see reference 22) . Single substitutions at critical residues can dramatically alter the antigenic specificity of this site (14, 28, 36, 39, 52) . Thus, point mutations resulting in such critical substitutions in circulating FMDV may occasionally render a vaccine based on site A alone ineffective. Results on the extent of cross-protection of such vaccines are still very limited and inconclusive (21, 27) .
Alternative approaches to synthetic anti-FMD vaccines include cocktails of synthetic peptides representing variant sequences and/or empty capsids (31, 51) , which may present the immune system with several independent continuous epitopes as well as assembled epitopes. Discontinuous epitopes in antigenic sites independent of site A have been identified in FMDV serotypes A (7, 53, 57) , 0 (29) , and C (23) , mainly by sequencing monoclonal antibody (MAb) escape mutants. These antigenic sites are as follows. (i) One site is the carboxy-terminal segment of VP1 (about 15 residues), termed site C. In FMDV of serotype 0, site C forms with site A a discontinuous antigenic domain, termed site 1 (29, 44, 45, 58) . However, sites A and C appear as independent continuous sites in serotype C (23, 39, 40) . (ii) Another site is a discontinuous antigenic domain located close to the capsid threefold axis. In FMDV type C, this domain appears as a major antigenic site (site D) (23) , which may be considered equivalent to sites 2 and 4 defined for type 0 (29) . This antigenic region includes the B-C loop of VP2 (residues 70 to 80) and the B-B "knob" of VP3 (residues 58 to 61) in serotypes C, 0, and A. A part of the VP1 carboxy terminus (around residue 193) is also involved in site D of FMDV type C. The VP2 E-F loop (residues 131 to 134) is involved in site 2 defined for FMDV type 0. (iii) There is another independent antigenic site located close to the capsid fivefold axis. In FMDV type 0, this site (designated site 3) involves the B-C loop of VP1 (residues 43 to 48) (29) . Some substitutions found in escape mutants within or around site 3 appear to modify the antigenicity of site A (43) . A site equivalent to site 3 occurs at least in FMDV type A; this site includes the H-I loop of VP1 (around residue 170) (7, 57) . Finally, some epitopes found in FMDV type A, not assigned to any of the above-mentioned sites, involve other loops of VP3 (7, 57 Table 1 . Virions were concentrated by sedimentation through a sucrose cushion and for RNA extraction were further purified by sucrose density gradient centrifugation as described previously (18) .
MAbs. The neutralizing MAbs used have been previously characterized, and their epitopes have been located in different antigenic sites of FMDV (23, (38) (39) (40) (41) .
EID assays. The enzyme immunodot (EID) assays were carried out essentially as previously described (38) . Briefly, the amount of virus was determined by polyacrylamide gel electrophoresis and by reactivity with nonneutralizing MAb 7BH11 (which recognizes a conserved epitope; see Fig. 1 ), and an equal amount of each FMDV variant was applied to nitrocellulose sheets which were then saturated with 5% bovine serum albumin in phosphate-buffered saline. The sheets were incubated with three 10-fold serial dilutions of supernatants of hybridoma cultures, and the amount of MAb bound was determined enzymatically with goat anti-mouse immunoglobulin G-peroxidase (diluted 1:2,000; Bio-Rad) and 4-chloro-1-naphthol as a substrate. Dots were quantified with a JoyceLoebl densitometer.
Nucleotide sequencing. The nucleotide sequences of the genomic region P1 encoding the capsid proteins of C1 Haute Loire-Fr/69 and C3 Argentina/85cl (in a virus designation, cl denotes that the virus was plaque purified) were determined with viral RNA essentially as described previously (26) . Purified RNAs of C5 Argentina/69 and C1 Serra Daro-Sp/81 (C-S15) were reverse transcribed to DNAs, and these were amplified by PCR and sequenced with the Femtomol sequencing kit (Promega). The region corresponding to the aminoterminal part of VP4 of C-S15 was sequenced to complete the P1 sequence previously determined for this virus (54) .
Determination of potential accessibility to antibodies of capsid residues. The atomic coordinates of FMDV Cl Santa Pau-Sp/70cl (C-S8cl) have been determined at 3.5-A (0.35-nm) resolution (1, 16, 23) . The accessible surface area of C-S8c1 was calculated by the method of Lee and Richards (30) . The accessible area is defined as the continuous path of the center of a spherical probe as it is rolled over the protein surface. For multimeric proteins, the calculation of accessible area may be made for the unique portion but must be 
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performed in the context of the whole assembly. For FMDV, we achieve this by making the calculation for an icosahedral subunit in the context of a fringe of residues from symmetryrelated units. To ensure that we did not consider the internal surface of the capsid, residues were considered to be potentially external only if they were at a capsid radius greater than 125 A (12.5 nm) . Residues are considered to be probe accessible if their accessibility in the C-S8cl structure exceeds 10% of the amino acid accessibility in a Gly-X-Gly extended tripetide. Novotny (36, 38, 39) and have been adapted and included here for comparison with the EID data. EITB assays were not done (ND) for some combinations. The discrepancies (13% of the cases) did not affect the conclusions of our study. Some of the discrepancies (e.g., weak reactivity in the EID assay and no reactivity in the EITB assay) may be explained by the higher sensitivity of the former assay (38 Table 1 ). In contrast, a significant degree of antigenic variation in site D was observed among isolates from Argentina and Uruguay (sublines III, IV, and V), even among viruses of the same subline. The epitope at site D recognized by MAb 1G5 was the only one strictly conserved among the viruses analyzed.
To compare the extent of variation of site D with that of site A, we tested the reactivities of the South American isolates listed in Fig. 1 with a panel of 18 neutralizing MAbs, directed to at least 14 different continuous epitopes in site A and 2 epitopes in site C, by using the EID assay (Fig. 2) . Antigenic heterogeneity detected with site A MAbs was similar to that detected with site D MAbs. For example, the proportion of positive reactivities obtained with viruses from South America and with MAbs elicited with subtype C1 viruses and directed to site A epitopes was 43%, whereas the same calculation with MAbs directed to site D epitopes was 49% (compare Fig. 1 and  2 ; for this comparison, we excluded the MAbs raised against C3 FMDVs since these MAbs were all directed to site A). Thus, the degree of antigenic variability was not substantially higher in site A than in site D, in spite of the former being composed of continuous epitopes in a flexible loop and the latter being composed of discontinuous epitopes at the interface of three proteins.
Limited sequence variation in each of several antigenic sites of FMDV can give rise to antigenically highly divergent viruses. We have previously reported that the serologically different FMDVs C3 Resende-Br/55 and C3 Argentina/84 were indistinguishable in the amino acid sequence of antigenic site A but differed at other antigenic sites (25) . 2). C5 Argentina/69 is so serologically highly divergent in relation to all other type C viruses (5) that it has been classified as a new subtype (46) . However, C1 Haute Loire-Fr/69 is not serologically different from other European C1 isolates. This apparent discrepancy between serological results and MAb results was solved by comparing the reactivities of type C viruses with MAbs directed to epitopes within antigenic site D (Fig. 1) . Site D of C5 Argentina/69, but not that of C1 Haute ""None" indicates that the differences were found outside the capsid scgments identified as antigenic (sce Fig. 3 ). Antigenic site 3 has been identified in FMDV serotypes 0 (29) and A (57) but not in serotype C (see the introduction). h Secondary structure assignments are as in Fig. 3 . Loire-Fr/69, showed a substantially divergent antigenic specificity when compared with other genetically related viruses.
We have explored the molecular basis of the antigenic differences among these and other type C viruses analyzed with MAbs by comparing the complete capsid sequences of the viruses. The nucleotide sequences of the RNAs encoding the capsid proteins of C, Haute Loire-Fr/69, C5 Argentina/69, and C3 Argentina/85cl were determined, and the deduced amino acid sequences (Fig. 3) were compared with those previously determined for seven additional field isolates of FMDV type C (25, 35) . The alignment includes derived consensus sequences for European and American viruses (Fig. 3) . By using the atomic coordinates obtained by X-ray crystallography of FMDV C-S8cI (1, 16, 23), the amino acids of the capsid which ""None" indicates that the differences were found outside the capsid segments defined as antigenic (sec Fig. 3 ). In spite of not belonging to any of these segments, amino acid 54 is included within sitc D because it is located at the center of the structural domain corresponding to site D (23). Antigenic site 3 has becn identified in FMDV serotypes 0 (29) and A (57) but not in serotype C (see the introduction).
"Secondary structure assignments are as in Fig. 3 . are accessible to a surface probe with a radius of 2 A (0.2 nm) have been determined (Fig. 3) . We have considered the possibility that such residues may also be accessible to antibodies and could potentially contribute to antigenicity (42) . In addition to the accessible residues determined, all the available structural evidence (2, 32, 43) as well as the immunological and genetic evidence (Fig. 3) suggests that VP1 residues 133 to 152 within the G-H loop (which correspond to antigenic site A and were found disordered in FMDV C-S8c1) are also exposed on the virion surface. Considering that the antigenically most divergent type C viruses from Europe and South America currently available-some of which are thought to have escaped immunity conferred by the vaccines in use (4, 9, 34, 46) -are included in the alignment of Fig. 3 , there is a remarkably limited number of amino acid differences among them. The amino acid sequence identity between any two viruses is higher than 92%, and the identity between the consensus sequences for European and American viruses is 96%. The capsids of the three subline II viruses compared (C1 Haute Loire-Fr/69, C-S8cl, and C-S15) differ only in 9 to 10 surface amino acids ( (Fig. 3) . Figure 4 shows that most positions which differ between these two viruses are at the tips of surface loops and are highly accessible to antibodies. All but two of the exposed residues (F-11 --Y and Q-218 -> R in VP3) are located within known antigenic sites of FMDV (Table 3 ). The critical residue replaced at VP1 position 146 within site A, which is responsible for the extreme antigenic divergence of C5 Argentina/69 detected with site A MAbs (36), has been found repeatedly replaced in MAb escape mutants (28, 39, 40 (Fig. 3) .
h Secondary structure assignments are as in Fig. 3 .
The consensus amino acids are derived from the 11 sequences shown in Fig. 3 . with C3 Resende-Br/55. The majority of differences in residues located at the capsid surface are within or vcry close to the four previously idcntified antigenic sitcs of FMDV (Fig. 3) . Analysis with MAbs ( Fig. 1 and 2 (Table 4) . A substitution at position 74 of VP2 was found in most serological variants tested; replacements at this position may have a particularly drastic effect on the antigenic specificity of site D (compare Fig. 1 and Table 4 ). On the other hand, the serological divergence of C, viruses relative to C3 ResendeBr/55 may be explained by differences in site A and perhaps in site 3 but not in site D (compare site D sequences and antigenicities of these viruses in Table 4 and Fig. 1 ). Finally, in spite of its being classified as a different subtype, C, PandoUr/44 reacted in a manner very similar to that of C3 ResendeBr/55 with MAbs directed to sites A and D. However, several of the exposed amino acids in the B-C, F-G, and H-I loops of VP1 (within or around antigenic site 3) of C, Pando-Ur/44 were unique to this virus (Fig. 3) and may contribute to its serological divergence. This possibility cannot be tested at present since no MAbs directed to site 3 of FMDV type C are available.
DISCUSSION
Lack of correlation between genetic distance and antigenic divergence. The above-described results as well as the previous distinction between antigenically noncritical and critical residues within site A of FMDV-which can lead to antigenic diversification either through a gradual increase in antigenic distance mediated by accumulation of amino acid replacements or through drastic changes in antigenic specificity caused by single replacements, respectively (36)-point to a frequent lack of correlation within a FMDV serotype between genetic distance and antigenic divergence. FMDV C GC-Ger/26 (C GC), an early isolate which belongs to an evolutionary subline now probably extinct (35) , is genetically the most divergent of the type C viruses which have been sequenced (Fig. 3) . The capsid sequence of C GC differs from the consensus sequence for subtype C, in 46 amino acids, 40 of them outside antigenic segments as depicted in Fig. 3 . In spite of such a considerable number of replacements, the overall reactivity of C GC with MAbs directed to three independent antigenic sites identified in type C is not substantially different from the recactivities of other C, viruses (see reference 38 for site A and Fig. I for site D), and C GC has served as a reference strain for the subtype C, viruses (46) . The situation with C GC is in clear contrast to other examples described in Results concerning genetically closely related isolates of the same evolutionary subline which were nevertheless antigenically dissimilar. C5 Argentina/69 is an extreme case of an antigenically highly divergent isolate ( Fig. 1 and 2) classified as a new serological subtype in spite of belonging to the same evolutionary subline as C3 ResendeBr/55 and other subtype C3 viruses.
Each identified antigenic site may play a role in antigenic diversification of FMDV in the field. The striking genetic similarity of C5 Argentina/69 to C3 Resende-Br/55, the vaccinc strain used in Argentina at the time of the emergence of C5 Argentina/69, may suggest that the former virus arose from the vaccine strain itself (8) . Remarkably, most of the few surface amino acids replaced were located within the three major antigenic sites which have been identified in FMDV (Fig. 4) . Thus, it seems that the emergence of new, highly divergent FMDV subtypes can occur through a mechanism of antigenic drift involving a very limited number of critical amino acid substitutions in the several identified antigenic sites. Significant variation in several antigenic sites relative to C3 Resende-Br/55 was also detected in C3 Argentina/85, a serological variant which replaced C3 Resende-Br/55 as the type C vaccine strain in Argentina. Other serological variants (e.g., C3 Argentina/84, C4 Tierra del Fuego-Arg/66, and Cl Haute Loire-Fr/69) differed in some but not all sites (see Results). In general, most of the capsid surface residues which differed among serological variants of FMDV type C were located within antigenic sites. These observations suggest that every antigenic site identified in FMDV is relevant to the recognition of the virus by the immune systems of target animals. Each antigenic site has participated, to a different extent depending on the isolates considered, in antigenic variation in nature. G-H loop and VP2 allows the loop to adopt a stable conformation (32), although even in this structure the loop remains among the most mobile surface-exposed regions. Thus, it may be less subject to structural constraints than other more rigid antigenic domains. The sequence hypervariability of site A may therefore reflect not only the selection exerted by the immune system but also tolerance of replacements fixed by chance events independently of immune selection (12, 19, 33) . In contrast to site A, the discontinuous antigenic site D-at an area of contact between VP1, VP2, and VP3-shows more limited numbers and types of amino acid replacements.
In fact, while the G-H and B-C loops of VP1, corresponding to sites A and 3, respectively, have been long recognized as hypervariable between serotypes and within a serotype (Fig. 3) , the loops involved in site D epitopes are less variable in sequence (Fig. 3) , even when different serotypes are compared (results not shown). The positions replaced within site D in field isolates of type C often coincide with positions repeatedly replaced in MAb escape mutants (Table 4) . Air et al. (3) have noted that the limited number of substitutions selected by MAbs against influenza virus epitopes suggests that the number of amino acid changes which can lead to selection of new, epidemic-causing influenza viruses by antigenic drift may be very limited. Those authors suggest that the substituted amino acids may be those critically involved in interactions with the selecting antibody. However, our work (23) on mapping MAb escape mutations onto the structure of FMDV C-S8c1 suggests that structural constraints at antigenic site D may also significantly limit the mutations seen. The analysis of field variants of FMDV presented in this paper supports this view and suggests that, as for influenza virus, the variety of mutations leading to antigenic drift in FMDV may be highly restricted. However, the very few replacements found within site D of FMDV type C, and their combinations, must suffice to explain the high level of antigenic variation detected in this site. Thus, a limited number of tolerated replacements within epitopes does not necessarily preclude substantial antigenic variation.
In conclusion, antigenic variation of FMDV in the field is not determined solely by amino acid substitutions at the hypervariable site A within the G-H loop of VPI. Rather 
